PF-Atlas › Clinical Trials › NCT05134727
Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants
AZD5055 · Phase 1
Registry ID
NCT05134727
Phase
Phase 1
Status
Completed
Drug / intervention
AZD5055
Sponsor
AstraZeneca
Start
2021-11-18
About this trial
AZD5055 is evaluated in NCT05134727, a Phase 1 idiopathic pulmonary fibrosis study sponsored by AstraZeneca. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05134727 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.